本文選題：癌 + 肝細(xì)胞��； 參考：《腫瘤》2017年10期

【摘要】：肝細(xì)胞肝癌(hepatocellular carcinoma,HCC)是人類常見(jiàn)的惡性腫瘤,在所有惡性腫瘤中其死亡率位居第3位。目前,索拉非尼是晚期HCC唯一批準(zhǔn)上市的分子靶向治療藥物。然而,索拉非尼在晚期HCC中的治療效果并不理想,存在較大的個(gè)體差異。為了優(yōu)化晚期HCC患者的治療方案,減少醫(yī)療支出,改善患者的生活質(zhì)量,人們對(duì)預(yù)測(cè)索拉非尼治療晚期HCC療效生物標(biāo)志物的研究越來(lái)越重視。研究表明,腫瘤組織中磷酸化細(xì)胞外調(diào)節(jié)蛋白激酶(phosphorylated extracellular signal regulated kinase,p ERK)、c-Jun氨基末端激酶(c-Jun N-terminal kinase,JNK)信號(hào)通路下游的c-Jun磷酸化水平和血管內(nèi)皮生長(zhǎng)因子受體2(vascular endothelial growth factor receptor-2,VEGFR-2)的表達(dá)水平,血清中甲胎蛋白(alpha-fetoprotein,AFP)、轉(zhuǎn)化生長(zhǎng)因子(transforming growth factor,TGF)和血管內(nèi)皮生長(zhǎng)因子(vascular endothelial growth factor,VEGF)的濃度,以及循環(huán)腫瘤細(xì)胞中p ERK和磷酸化蛋白激酶B(protein kinase B,PKB,又稱Akt)的表達(dá),是預(yù)測(cè)索拉非尼療效的重要因素,具有作為新的生物標(biāo)志物的應(yīng)用前景。本文對(duì)近年來(lái)的相關(guān)臨床隊(duì)列研究進(jìn)行綜述。
[Abstract]:Hepatocellular carcinoma (HCC) is a common malignant tumor in human, and its mortality rate ranks third among all malignant tumors. Currently, sorafenib is the only molecular targeted therapy approved for advanced HCC. However, the efficacy of Solafenib in the treatment of advanced HCC is not satisfactory, and there are significant individual differences. In order to optimize the treatment plan of advanced HCC patients, reduce medical expenses, improve the quality of life of patients, people pay more and more attention to the biomarkers of predicting the efficacy of Solafenil in the treatment of advanced HCC. The results showed that phosphorylated extracellular signal regulated kinase phosphorylated protein kinase phosphorylation and expression of vascular endothelial growth factor receptor 2(vascular endothelial growth factor receptor 2 (VEGFR-2) downstream of c-Jun N-terminal kinase signaling pathway. Serum levels of alpha-fetoprotein (growth), transforming growth factor (growth) and vascular endothelial growth factor (endothelial growth), and the expression of pERK and phosphorylated protein kinase (PKB) in circulating tumor cells. It is an important factor to predict the curative effect of Solafenib and has the prospect of application as a new biomarker. This article reviews the clinical cohort studies in recent years.
【作者單位】： 復(fù)旦大學(xué)附屬中山醫(yī)院肝癌研究所;復(fù)旦大學(xué)上海醫(yī)學(xué)院;
【分類號(hào)】：R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張小麗;王鴻;;索拉非尼及其抗腫瘤作用[J];安徽醫(yī)藥;2008年03期

2 逯華;陳日新;;多激酶抑制藥索拉非尼的研究進(jìn)展[J];右江民族醫(yī)學(xué)院學(xué)報(bào);2008年04期

3 祁慧薇;范理宏;;索拉非尼抑制人非小細(xì)胞肺癌細(xì)胞的增殖并誘導(dǎo)其凋亡[J];腫瘤;2011年12期

4 王玉蘭;林挺巖;陳湘琦;;索拉非尼抗腫瘤作用的研究現(xiàn)狀與進(jìn)展[J];中國(guó)醫(yī)藥指南;2011年33期

5 楊柳青;秦叔逵;龔新雷;劉秀峰;華海清;夏兆s，

本文編號(hào)：1999921